Yahoo · Sep 3, 2026
Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
AC
NASDAQ · ACRV
Acrivon Therapeutics, Inc. Common Stock
Healthcare · Biotechnology
$2.00
Down-$0.04 (-1.96%)
Updated Sep 12, 2026, 11:06 AM
SID Score
6.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 47.65M
- P/E ratio
- -0.71
- Dividend yield
- 0.00%
- 52-week range
- $1.27 – $2.39
- Volume
- 461.59K
- Avg. volume
- 1.62M
Price performance
ACRV price history
1M range · 20 trading sessions · Daily adjusted prices
ACRV closed at $2.00 after 20 trading sessions, up 2.56% for the selected period.
- Last close
- $2.00
- Period change
- +2.56%
- Period low
- $1.95
- Period high
- $2.39
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $2.05 | $2.06 | $1.95 | $2.00 | 461.59K |
| Sep 10, 2026 | $2.03 | $2.06 | $1.96 | $2.04 | 323.97K |
| Sep 9, 2026 | $2.10 | $2.17 | $1.99 | $1.99 | 239.12K |
| Sep 8, 2026 | $2.13 | $2.175 | $2.07 | $2.10 | 129.98K |
| Sep 4, 2026 | $2.06 | $2.14 | $2.055 | $2.13 | 184.6K |
| Sep 3, 2026 | $2.15 | $2.15 | $2.045 | $2.06 | 118.79K |
| Sep 2, 2026 | $2.07 | $2.20 | $2.05 | $2.15 | 131.32K |
| Sep 1, 2026 | $2.07 | $2.125 | $2.025 | $2.07 | 356.52K |
| Aug 31, 2026 | $2.04 | $2.11 | $2.0209 | $2.09 | 160.29K |
| Aug 28, 2026 | $2.16 | $2.1899 | $2.05 | $2.06 | 217.93K |
| Aug 27, 2026 | $2.11 | $2.20 | $2.08 | $2.15 | 188.35K |
| Aug 26, 2026 | $2.17 | $2.19 | $2.08 | $2.08 | 160.13K |
| Aug 25, 2026 | $2.19 | $2.255 | $2.17 | $2.18 | 243.11K |
| Aug 24, 2026 | $2.19 | $2.225 | $2.06 | $2.20 | 171.49K |
| Aug 21, 2026 | $2.21 | $2.31 | $2.18 | $2.21 | 361.33K |
| Aug 20, 2026 | $2.33 | $2.37 | $2.17 | $2.20 | 499.43K |
| Aug 19, 2026 | $2.06 | $2.39 | $2.06 | $2.39 | 731.49K |
| Aug 18, 2026 | $2.05 | $2.065 | $1.97 | $2.05 | 336.37K |
| Aug 17, 2026 | $2.11 | $2.14 | $1.96 | $2.05 | 1.5M |
| Aug 14, 2026 | $1.90 | $1.99 | $1.85 | $1.95 | 758.08K |
Latest ACRV news
The latest Smart Investors Daily articles mentioning ACRV.
Stock researchCompany · Overview
ACRV research
Overview
Company profile and research snapshot.
Company profile
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $21.83
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 9, 2026 | Piper Sandler | Overweight | — |
| Nov 25, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2025 | Oppenheimer | Outperform | — |
| May 16, 2025 | Jones Trading | Hold | — |
| May 15, 2025 | Oppenheimer | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 2, 2026
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D
Yahoo · Aug 31, 2026
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategyWATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational
Yahoo · Aug 12, 2026
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts
ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026 ACR-2316 Phase 1/2 trial in AP3-prioritized tumor types advancing in randomized dose expansion phase supported by a promising, favorable safety profile and durable single-agent clinical activity in several tumor types Cash, cash equivalents, and marketable securities of $90.0 million as of June 30, 2026 expected to fund operations into fourth quart
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
